Gene networks constructed through simulated treatment learning can predict proteasome inhibitor benefit in Multiple Myeloma.

CONCLUSIONS: STLsig can identify gene signatures that could aid in treatment decisions for MM patients and provide insight into the biological mechanism behind treatment benefit.
PMID: 32913136 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - September 9, 2020 Category: Cancer & Oncology Authors: Ubels J, Sonneveld P, van Vliet MH, de Ridder J Tags: Clin Cancer Res Source Type: research